<DOC>
	<DOCNO>NCT01146938</DOCNO>
	<brief_summary>To compare evaluate pharmacokinetic characteristic safety fimasartan hepatic impairment patient healthy volunteer</brief_summary>
	<brief_title>A Clinical Trial Compare Evaluate Pharmacokinetic Characteristics Safety Fimasartan Hepatic Impairment Patients Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>&lt; Hepatic impairment patient &gt; age : 20 64 year sex : male ChildPugh score A ChildPugh score B body weight : great 55 kg write informed consent &lt; Healthy volunteer &gt; age : 20 64 year sex : male body weight : great 55 kg write informed consent &lt; Hepatic impairment patient &gt; portosystemic shunt surgery ChildPugh score C creatinine clearance &lt; 80mL/min ascites &lt; Healthy volunteer &gt; AST ( SGOT ) , ALT ( SGPT ) &gt; 1.5 time Upper Normal Range Total bilirubin &gt; 1.5 time Upper Normal Range positive drug alcohol screening</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>fimasartan</keyword>
	<keyword>hepatic impairment</keyword>
</DOC>